Literature DB >> 3496917

In vivo evidence of intravascular binding sites for coagulation factor IX.

D M Stern, G Knitter, W Kisiel, P P Nawroth.   

Abstract

Previous studies have demonstrated that factors IX/IXa bind to specific sites on the surfaces of cultured and native endothelium in vitro and that these sites should be occupied with factor IX in homeostasis. Since factor IX of different species binds to endothelium in a similar manner, we examined if infusion of heterologous factor IX into an animal should result in displacement of host factor IX antigen from its vessel wall site. Experiments were carried out in baboons with a large excess of bovine factor IX employing species-specific radioimmunoassays. The results indicate that infusion of bovine factor IX or active site-blocked factor IXa, but not prothrombin, resulted in a dose-dependent rise in the plasma level of baboon factor IX antigen. This suggested that the infused factor IX was displacing the host clotting factor from some reservoir easily accessible to the intravascular space. Consistent with this hypothesis, infusion of 125I-factor IX demonstrated accumulation in multiple organs. Radioiodinated factor IX comigrating with the initial tracer on SDS-PAGE could be eluted from the luminal surface of pulmonary artery and aortic segments. 125I-factor IX was not significantly associated with cellular elements of the blood. These results suggest that there is a pool of non-circulating factor IX which is accessible to the intravascular space, widely distributed and involves endothelium.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496917     DOI: 10.1111/j.1365-2141.1987.tb01303.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Authors:  M W Nolte; T C Nichols; J Mueller-Cohrs; E P Merricks; I Pragst; S Zollner; G Dickneite
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

Review 2.  Advances and innovations in haemophilia treatment.

Authors:  Rob Peters; Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

3.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

4.  Evidence of clinically significant extravascular stores of factor IX.

Authors:  D Feng; K A Stafford; G J Broze; D W Stafford
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

5.  Thrombin and factor Xa enhance the production of interleukin-1.

Authors:  A Jones; C L Geczy
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

6.  Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Authors:  T C Nichols; H W G Franck; C T Franck; N De Friess; R A Raymer; E P Merricks
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

Review 7.  Endothelial-dependent procoagulant and anticoagulant mechanisms. Recent advances in understanding.

Authors:  C R Benedict; R Pakala; J T Willerson
Journal:  Tex Heart Inst J       Date:  1994

Review 8.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

9.  Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.

Authors:  C R Benedict; J Ryan; B Wolitzky; R Ramos; M Gerlach; P Tijburg; D Stern
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 10.  New developments in the management of moderate-to-severe hemophilia B.

Authors:  Moniba Nazeef; John P Sheehan
Journal:  J Blood Med       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.